An in-trial dendritic cell vaccine that fights malignant brain tumors called glioblastoma multiforme (GBM) may help boost a patient's immunity response and improve the outcome, a new report says. An article in the July 15 issue of Cancer Research says this would mark the first time a tumor-altering therapeutic intervention would have shown such promise.

Full story: medicinenet.com